A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease

NCT02577523 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson's Disease

Interventions

DRUG: ND0612 (Levodopa/Carbidopa solution)
DRUG: ND0612 (Levodopa/Carbidopa solution) + morning oral IR-LD/CD

Sponsor

NeuroDerm Ltd.